Page 54 - วารสารกรมการแพทย์แผนไทยฯ ปีที่ 11 ฉบับที่ 2

158 «“√ “√°“√·æ∑¬å·ºπ‰∑¬·≈–°“√·æ∑¬å∑“߇≈◊Õ° ªï∑’Ë 11 ©∫—∫∑’Ë 2 情¿“§¡- ‘ßÀ“§¡ 2556

(Gastritis), ∑âÕߺŸ° (Constipation), °“√°¥∑—∫ ®”π«π 91 √“¬ ¡“°°«à“„π°≈ÿà¡Ωí߇¢Á¡®’π √à«¡°—∫

√“°ª√– “∑ —πÀ≈—ß (Sciatica), °≈ÿà¡‚√§À¡Õπ√Õß °“√„™â¬“ ¬“√—°…“ÀÕ∫À◊¥ (84.6%) „πºŸâªÉ«¬ 91 √“¬
9
°√–¥Ÿ° —πÀ≈—ß à«π‡Õ« (Lumbar Disc Disease), ß“π«‘®—¬¢Õß Cui J ·≈–§≥– æ∫«à“ °“√Ωíß
‚√§·º≈„π°√–‡æ“–Õ“À“√ (Peptic Ulcer), ¿Ÿ¡‘·æâ ‰À¡‡¢â“®ÿ¥Ωí߇¢Á¡·°âÀÕ∫À◊¥„πÀπŸ«‘ μ“√å (®”π«π 8

(Allergic Rhinitis), ‚√§ª«¥‡ âπª√– “∑„∫Àπâ“ μ—« ®“° 32 μ—«) ∑”„Àâ “¡“√∂≈¥°“√Õ—°‡ ∫„π∑“ß
(Trigeminal Neuralgia), ‚√§ÀÕ∫À◊¥ (Asthma), ‡¥‘πÀ“¬„®‰¥â ‚¥¬«—¥®“°°“√Õ—°‡ ∫¢Õ߇´≈≈å (In-
‚√§≈”‰ â„À≠àÕ—°‡ ∫‡ªìπ·º≈‡√◊ÈÕ√—ß (Ulcerative flammatory Cell), ICAM 1, NP-Kappa B ®“°

Colitis), ‚√§‡ âπª√– “∑Õ—°‡ ∫À≈“¬·Ààß (Multiple °“√≈â“ßÀ≈Õ¥≈¡ (Bronchial Lavarge) ´÷Ëß≈¥≈ß
Neuritis), ¿“«–μ—«‡μ’Ȭ (Short Stature), ‰¡‡°√π ¡“°°«à“°≈ÿࡧ«∫§ÿ¡·≈–°≈ÿà¡∑’ˉ¥â√—∫¬“‡¥°´“‡¡∑“

(Migrane), º◊Ëπ§—πμ“¡º‘«Àπ—߇ªìπæ‘… (Urticaria) ‚´π (Dexamethazole) Õ¬à“ß¡’π—¬ ”§—≠
6 10
®“°°“√»÷°…“ Li J ·≈–§≥– „π°≈ÿࡺŸâªÉ«¬ ß“π«‘®—¬¢Õß Ming-juF ·≈–§≥– æ∫«à“
‚√§ªÕ¥Õÿ¥°—Èπ‡√◊ÈÕ√—ß (COPD) ®”π«π 60 √“¬ ·∫àß °“√Ωí߉À¡·°âÀÕ∫À◊¥„πºŸâªÉ«¬‚√§ÀÕ∫À◊¥ (Bron-

‡ªìπ 2 °≈ÿà¡Ê ≈– 30 √“¬ æ∫«à“ °“√Ωí߉À¡≈–≈“¬ chial Asthma) ®”π«π 112 √“¬ ‡ª√’¬∫‡∑’¬∫
‡¢â“®ÿ¥Ωí߇¢Á¡√à«¡°—∫°“√„™â¬“·ºπªí®®ÿ∫—𠇪√’¬∫ °—∫°“√Ωí߇¢Á¡ ®”π«π 107 √“¬æ∫«à“ ¡’ª√– ‘∑∏‘¿“æ

‡∑’¬∫°—∫Õ’°°≈ÿà¡∑’ˉ¥â√—∫°“√¬“‡æ’¬ßÕ¬à“߇¥’¬« æ∫«à“ „π°“√√—°…“¡“°°«à“ (89.3% μàÕ 72.9%)
11
°≈ÿà¡∑’ˉ¥â√—∫°“√Ωí߉À¡ ¡’°“√≈¥Õÿ∫—쑇Àμÿ°“√‡°‘¥ ®“°°“√»÷°…“¢Õß Cardwell W ´÷Ëß∑”‡ªìπ
ÀÕ∫À◊¥°”‡√‘∫√ÿπ·√߉¥â Õ¬à“ß¡’π—¬ ”§—≠ (P<0.05) Prospective, single-blinded randomized, pla-

√«¡∑—Èß Score of Cough, Expectoration ·≈– cebo - controlled trial with matched pairing
Chest Oppression ≈¥≈ßÕ¬à“ß¡’π—¬ ”§—≠ (P<0.01) of participants æ∫«à“°“√Ωí߇¢Á¡„πºŸâªÉ«¬‚√§ªÕ¥
7
Suzuki M ·≈–§≥– »÷°…“„π°≈ÿࡺŸâªÉ«¬‚√§ Õÿ¥°—Èπ‡√◊ÈÕ√—ß (COPD) ®”π«π 68 √“¬ æ∫«à“ ®”π«π
ªÕ¥Õÿ¥°—Èπ‡√◊ÈÕ√—ß (COPD) ®”π«π 68 √“¬ ·∫à߇ªìπ 34 √“¬∑’ˉ¥â√—∫°“√Ωí߇¢Á¡ ¡’§ÿ≥¿“æ™’«‘μ¥’¢÷Èπ „π 12
2 °≈ÿà¡Ê ≈– 34 √“¬ °≈ÿà¡·√° Ωí߇¢Á¡®√‘ß °≈ÿà¡ Õß —ª¥“Àå‚¥¬‡æ‘Ë¡ 6 minute walk (√–¬–∑“ß∑’ˇ¥‘π
‡ªìπΩí߇¢Á¡À≈Õ° ‚¥¬∑—Èß 2 °≈ÿࡉ¥â√—∫°“√Ωí߇¢Á¡ ‰¥â„π 6 π“∑’) √–¬–∑“߇æ‘Ë¡¢÷Èπ Õ¬à“߇ªìπ¡’π—¬ ”§—≠

—ª¥“Àå≈–§√—Èß®π§√∫ 12 —ª¥“Àå ·≈–ª√–‡¡‘π √à«¡°—∫ SPO2 ‡æ‘Ë¡¢÷Èπ·μà §à“ FEV1 ‰¡à‰¥â‡æ‘Ë¡¢÷Èπ
√à“ß°“¬æ∫«à“°≈ÿà¡∑’ˉ¥â√—∫°“√Ωí߇¢Á¡®√‘ß¡’ 6-minute Õ¬à“ß¡’π—¬ ”§—≠
12
walk (√–¬–∑“ß∑’ˇ¥‘π‰¥â„π 6 π“∑’) ‡æ‘Ë¡¢÷Èπ·≈–¥’ Linde K, Jobst K, Panton J ‰¥â∑”
¢÷ÈπÕ¬à“ß™—¥‡®π·≈–∑πμàÕ¿“«–‡Àπ◊ËÕ¬ÀÕ∫‡¡◊ËÕÕÕ° systemetic review „π 174 √“¬ ∑’ˉ¥â√—∫°“√Ωí߇¢Á¡
°”≈—߉¥â¥’¢÷Èπ (Dyspnea on Exertion: DOE) ‡æ◊ËÕ√—°…“ÀÕ∫À◊¥ æ∫«à“ °“√∑”ß“π¢Õߪե (Lung

„π°≈ÿà¡‚√§ÀÕ∫À◊¥ (Bronchial Asthma) Function) ¥’¢÷Èπ (3 „π 7 trials) ¥Ÿ®“°§à“ PEFR
8
®“°ß“π«‘®—¬¢Õß Liang C ·≈– Lun X æ∫«à“ °“√ ‡æ‘Ë¡¢÷ÈπÕ¬à“ß¡’π—¬ ”§—≠ 8.4 L/minute weight
Ωí߉À¡·°âÀÕ∫À◊¥√à«¡°—∫°“√„™â¬“√—°…“ÀÕ∫À◊¥¡’ mean difference (95% confidence interval 29.4-
ª√– ‘∑∏‘¿“æ„π°“√√—°…“∂÷ß 92.3% „π°≈ÿࡺŸâªÉ«¬ 46.2)